Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Basil K Williams, Hawaiian Eye 2022: Ocular Oncology – What’s New?

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 8th 2022

The field of ocular oncology is rapidly changing, according to a presentation at Hawaiian Eye 2022. We were delighted to speak with Dr Basil K Williams (University of Cincinnati, Cincinnati, OH, USA) about new developments in the field of ocular oncology.

The abstract entitled What’s New in the World of Ocular Oncology? was presented at Hawaiian Eye 2022, 15–21 January 2022.  

Questions

  1. Could you give us a brief overview of the field of ocular oncology? (00:20)
  2. What has been the impact of anterior segment optical coherence tomography on diagnosis and clinical examination? (01:00)

Speaker Disclosure: Basil K Williams is a consultant for Allergan, Castle Biosciences and Genentech.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of Hawaiian Eye 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup